Đang chuẩn bị liên kết để tải về tài liệu:
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

Nintedanib reduces the rate of decline in forced vital capacity in patients with idiopathic pulmonary fbrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib is 150 mg twice daily (BID). |